When was the last time you measured your waistline? If you assume that BMI is the only number to focus on when it comes to your health, think twice. New research has revealed a shocking revelation—your waist circumference might be a far better predictor of men's cancer risk than BMI.

The study finds that for each 4-inch increase in waist size, a man's risk of cancer increases by a staggering 25%. Meanwhile, BMI, commonly regarded as the gold standard for assessing obesity, raises cancer risk by only 19% for the same weight gain. So, if you've been dismissing that pesky belly fat, it's time to take notice.

But why is your waistline so important? The reason is visceral fat—the hidden, deep fat that accumulates around your organs. Unlike other body fat, visceral fat is a stealthy troublemaker, causing inflammation, insulin resistance, and abnormal blood fat levels—all of which combine to create a cancer-perfect storm.

Obesity has been associated with an increased risk of numerous health conditions, including cancer, for decades. The research, though, indicates that a specific measure of the body—waist circumference—may be an even more reliable forecaster of cancer risk in men than the more frequently employed Body Mass Index (BMI). This finding emphasizes the need to pay particular attention to the distribution of fat and not merely to the weight of the body.

BMI has been the go-to measure for years for gauging health risks related to obesity. New research, though, that appears in The Journal of the National Cancer Institute indicates that waist measurement is a better predictor of cancer risk in men. According to the research, four more inches (10 cm) around the waist will add 25% to a man's cancer risk. Conversely, a 3.7 kg/m² rise in BMI (from a BMI of 24 to 27.7) increased cancer risk by only 19%.

Why is waist circumference a better predictor, then? Unlike BMI, which measures weight relative to height, waist circumference actually measures abdominal fat—specifically, visceral fat. This type of fat encircles internal organs and is also linked to higher levels of inflammation, insulin resistance, and abnormal blood lipids, all of which are factors in cancer growth. BMI, however, does not measure fat distribution, so two individuals with the same BMI can have very different levels of health risk depending on where fat is deposited on their bodies.

Why Men Are at Higher Risk?

Interestingly, the research identified a significant difference between men and women when it came to waist circumference and cancer risk. Although waist circumference and BMI were linked with obesity-related cancers in women, the relationship was weaker than for men. An increase of 12 cm (4.7 inches) in waist size or a 4.3 rise in BMI (from 24 to 28.3) raised the cancer risk in women by just 13%—a much lower percentage than for men.

Experts credit this difference to the way that fat is stored in the body. Men are more likely to carry fat around the abdomen, especially as visceral fat, which is more metabolically active and associated with cancer-producing biological alterations. Women, by contrast, store fat in peripheral sites such as the hips and thighs, where it is less likely to drive systemic inflammation and metabolic disturbances.

A possible reason is that men tend to depot fat more in the visceral regions, whereas women tend to carry more subcutaneous and peripheral fat," wrote the researchers. "This may render waist circumference a more robust risk factor for cancer in men and account for why waist circumference provides additional risk information beyond BMI in men but not women."

Cancer Types Most Linked to Abdominal Fat

The research used the International Agency for Research on Cancer (IARC) data to define obesity-related cancers. These cancers are esophageal (adenocarcinoma), gastric (cardia), colorectal, rectal, liver, gallbladder, pancreatic, renal, and thyroid cancers, and multiple myeloma and meningioma. In men, abdominal obesity is especially significant in raising the risk of these cancers through high levels of insulin and markers of inflammation.

For women, the research proposes that both waist circumference and hip circumference may give a more accurate estimate of visceral fat and cancer risk. "Adding hip circumference to risk models could strengthen the link between waist circumference and cancer, especially in women," researchers observed.

What This Means for Men's Health and Cancer Prevention?

With these results, doctors advise men to be more mindful of their waistline than only their BMI. Waist size is an easy method to gauge health risk, and its maintenance through lifestyle changes might be the key to cancer prevention.

How To Reduce Cancer Risk In Men?

Track Your Waist Size: Regularly measure your waist circumference and try to keep it in a healthy range (below 40 inches for men, according to medical advice).

Eat a Balanced Diet: A diet containing high fiber, lean protein, and healthy fats can assist in limiting visceral fat gain.

Exercise Consistently: Regular exercise with a combination of aerobic and strength training will help maintain a healthy waistline.

Control Stress and Sleep: Persistent stress and inadequate sleep tend to cause weight gain, especially in the midsection of the body.

Regular Health Screenings: Early identification of cancer risk factors through regular screening can greatly enhance long-term health status.

Hepatitis remains one of the most misunderstood liver conditions, largely because it isn't a single disease but a group of infections—A, B, C, D, and E—each of which behaves very differently once it enters the body.

The question "can hepatitis be cured?" doesn't have one straightforward answer. The truth lies somewhere between full recovery and lifelong management, depending entirely on which type of hepatitis a person has contracted.

Not All Hepatitis Is the Same

Hepatitis A and E are generally short-lived infections. The liver, in most cases, clears these viruses naturally without any specific antiviral medication. Rest, hydration, a balanced diet, and avoiding alcohol are usually enough to help the body recover fully. Chronic infection is rare with these two types, and when it does occur, particularly with Hepatitis E in people with weakened immunity, it can still be treated successfully.

Hepatitis C tells a much more encouraging story. Thanks to advances in medicine, Direct-Acting Antivirals, or DAAs, now cure more than 95 percent of cases. These are oral tablets taken for roughly eight to twelve weeks, and they carry minimal side effects compared to older treatments. For patients diagnosed early, Hepatitis C is, quite genuinely, curable.

Where Treatment Manages Rather Than Cures

Hepatitis B and D are a different story altogether. When the infection is acute, the body often fights it off on its own without much trouble.

Chronic cases, though, are far tougher to deal with. As of now, no medication can fully remove the Hepatitis B virus from the body once it settles in. What doctors can do is keep it under control, usually through antiviral tablets or interferon injections, so that it doesn't quietly damage the liver over time and lead to cirrhosis or cancer. For many patients, this isn't a short course of treatment. It's something they may need to stay on for years, and in several cases, for the rest of their lives.

Hepatitis D is considered the more severe of the two, and it only shows up in people who already have Hepatitis B; it cannot infect someone on its own. Treatment choices here are still quite limited. A few newer drugs have shown some promise in keeping the disease in check, but nothing yet counts as an actual cure. When the liver damage has progressed too far, a transplant sometimes becomes the only way forward.

Why Early Diagnosis Changes The Outcome

The single most important factor in determining outcomes across all types of hepatitis is timing. Detected early, Hepatitis C can be eliminated. Detected early, Hepatitis B can be controlled well enough that liver damage never progresses. Left unchecked, however, both can silently damage liver tissue for years before symptoms even appear.

Regular liver function tests, hepatitis screening for those at risk, and vaccination—especially for Hepatitis B—remain the strongest tools available for prevention and timely intervention.

The Bottom Line

Hepatitis doesn't follow a single script, and that's something patients often find confusing at first. Some forms clear up completely with the right treatment, others require ongoing management to keep the virus in check, and in many cases, vaccination and timely screening make the real difference in avoiding complications down the line.

Knowing exactly which type of hepatitis one is dealing with is what allows a doctor and patient to set realistic expectations and work out a treatment plan that actually fits the situation.

The rise of GLP-1 medications such as Ozempic (semaglutide), Wegovy, Mounjaro, and Zepbound (tirzepatide) has transformed obesity and diabetes treatment.

However, soaring demand and earlier drug shortages also fueled the rapid growth of compounded GLP-1 drugs, which are now under increasing scrutiny from regulators and medical experts.

Over the past few months, the U.S. Food and Drug Administration (FDA) has intensified its crackdown on compounded GLP-1 products, warning that patients could face quality, dosing, and safety concerns if they obtain these medications from unlawful sources.

What Are Compounded GLP-1 Drugs?

A compounded drug is a medication that is custom-made by a licensed compounding pharmacy to meet an individual patient's specific medical needs. For example, removing an allergen, changing the dosage, or preparing a formulation that is not commercially available.

The FDA said, "Compounded drugs are not FDA-approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed."

Also read: People Are Microdosing GLP-1 Weight Loss Drugs; What Do Experts Have To Say About It?

Why Have Compounded GLP-1 Drugs Become Popular?

Demand for GLP-1 medications for weight loss skyrocketed worldwide between 2022 and 2025, leading to shortages of semaglutide and tirzepatide.

During these shortages, compounding pharmacies were legally allowed under specific circumstances to prepare several versions of these medications.

Many patients turned to compounded GLP-1s because they were often affordable, available, and easier to buy online.

Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real

FDA Is Tightening Scrutiny

FDA's efforts to restrict this practice include widespread compounding of semaglutide, tirzepatide, and liraglutide.

The agency has proposed excluding these drugs from the list of bulk substances used for large-scale compounding because FDA-approved alternatives are now available.

It has also issued warning letters to companies producing compounded GLP-1 products outside permitted circumstances.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

Recent Research Raises New Concerns

A new University of Colorado Anschutz Medical Campus secret shopper study published in July 2026 found that the compounded GLP-1 market remains active even after shortages have been curbed.

Researchers reported that many online pharmacies were still selling compounded semaglutide or tirzepatide, with some products originating from pharmacies lacking compounding licenses.

Potential Risks of Compounded GLP-1 Drugs

Inaccurate Dosing

Small differences in concentration may result in patients receiving too much or too little medication.

Sterility Concerns

Injectable medicines must be manufactured under strict sterile conditions. Improper preparation increases the risk of contamination.

Different Ingredients

Some compounded products have reportedly used semaglutide salts or added vitamins and other substances that are not present in FDA-approved versions. The FDA has previously stated that certain semaglutide salt forms have not been demonstrated to be safe or effective.

Limited Safety Data

Because compounded products are not FDA-approved, they have not undergone the rigorous clinical trials evaluating effectiveness, manufacturing consistency, and long-term safety.

Counterfeit or Unregulated Products

Experts warn that some websites advertise compounded GLP-1 medications that may not come from legitimate pharmacies at all.

As GLP-1 medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) continue to help manage metabolic disorders and obesity, a new trend is rapidly gaining traction on social media - GLP-1 microdosing.

Instead of taking the prescribed doses approved for diabetes or obesity, some users are deliberately taking much smaller amounts, claiming they can lose weight, reduce food noise, avoid side effects, save money, or even improve longevity.

However, experts warn that there is currently little scientific evidence that GLP-1 microdosing is safe or even effective.

What Is GLP-1 Microdosing?

Some people reduce their dose by extending the time between injections, counting "clicks" on injection pens instead of using prescribed doses, or taking customized low-dose formulations.

HealthandMe spoke to Dr. Shehla Shaikh, Consultant Endocrinologist, Saifee Hospital, Mumbai, about the trend of GLP-1 microdosing.

Dr. Shaikh says, "The lowest dose that is supported by evidence for semaglutide is 0 25 mg. While, for tirzepatide, it is 2 5 mg Some people are using much smaller amounts for example using nine clicks on a semaglutide pen which gives about 0 06 mg. Now there are no randomized studies or clear guidelines that show if this kind of micro-dosing is safe or works."

Also read: Can GLP-1 Drugs Like Ozempic, Mounjaro Cause Hair Loss? Study Says It's Rare But Real

Medical experts caution that these practices fall outside approved prescribing guidelines and have not been rigorously studied.

The expert says, "One big worry is how accurate the dose is. These injectable pens are made to give set approved amounts; not amounts based on people counting clicks. Even a small mistake in counting can mean taking too little medicine which may not work well or too much, which could cause more problems. Since these instructions are complicated, they need careful handling good eyesight and understanding of the device."

Why Are People Trying It?

Fewer Side Effects

Lower Cost

These medications are expensive in various countries. So, people stretch a single prescription by taking less medication than prescribed.

Weight Maintenance

Rather than pursuing significant weight loss, some users say they simply want to maintain previous results or reduce constant food cravings without taking full doses.

Longevity Claims

Online influencers have begun promoting low-dose GLP-1s as potential "longevity drugs." While GLP-1 medications show promise for heart and metabolic health, experts stress that these benefits have only been demonstrated using clinically tested doses, not microdoses.

Also read: Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads: Should GLP-1 Users Be Concerned?

The Risks of Microdosing

Reduced Effectiveness

Taking too little medication may fail to adequately suppress appetite, improve blood sugar levels, or achieve meaningful weight loss.

Dr. Shaikh says, "People often choose microdosing because they want to avoid problems reduce appetite with a smaller dose or make a costly medicine last longer. While smaller amounts might help a bit, current information shows that the best and steadiest results come from following the approved ways to take the medicine. Using doses that are too low might not give the results to people who want to lose weight or manage their metabolic health."

Delayed Medical Treatment Or Risk Of Expiration

Experts also say that people with obesity or diabetes could unknowingly receive suboptimal treatment while believing they are protected. Another problem is how long the medicine lasts after it is opened.

Dr. Shaikh explains, "An opened semaglutide pen should be used within 60 days while an opened tirzepatide pen should be used within 30 days. Because microdosing uses the medicine over a longer time, people might keep using it past the time it is safe which could change how good it is."

Inaccurate Dosing

Also read: Could GLP-1 Weight Loss Drugs Help People Take Fewer Sick Days? New Study Says So

Some users manually estimate doses by counting injection pen clicks. Experts warn these devices are designed to deliver specific calibrated doses, making partial dosing unreliable.

The expert says, "Some people think micro-dosing gives similar benefits with fewer problems or lower costs, but this practice has no scientific support and might have several dangers."